Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06174922
Other study ID # Int/IEC/2023/SPL-1026A
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date December 1, 2023
Est. completion date March 2026

Study information

Verified date April 2024
Source Post Graduate Institute of Medical Education and Research, Chandigarh
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The investigators hypothesize that a combination of prednisolone and itraconazole would significantly reduce the exacerbation rate at one-year of patients with acute allergic bronchopulmonary aspergillosis (ABPA) compared to itraconazole or prednisolone monotherapy. In this study, 300 subjects aged ≥18 years with acute ABPA will be randomized to treatment with either prednisolone, itraconazole, or prednisolone plus itraconazole, all for four months each. After collecting baseline demographic, immunologic, and imaging data, the investigators will follow the patients every 2 months for the first two visits and then every four months for three visits. The primary outcome will be the proportion of subjects experiencing exacerbation (asthma or ABPA) 12 months after treatment completion.


Description:

The principles of treating ABPA include using glucocorticoids to control the immunologic activity and antifungal agents to attenuate the fungal burden in the airways.4 Glucocorticoids are the first line treatment in acute stages of ABPA, although there are no placebo-controlled trials of glucocorticoids in ABPA. However, their effectiveness in ABPA is so well established that it might be considered unethical to conduct placebo-controlled trials. In one study, 92 subjects were randomized to receive high-dose (n=44) or low-dose (n=48) prednisolone. The numbers of subjects with exacerbation after one year (high-dose: 40.9% vs. medium-dose: 50%, p=0.59) were similar in the two groups. Although the composite response rates were significantly higher in the high-dose group, the improvement in lung function and the time to first exacerbation were similar in the two groups. [Eur Respir J. 2016;47(2):490-498] Specific antifungal agents in ABPA can modify the immune response by removing or reducing the antigenic stimulus consequent to a decreased fungal burden. Two randomized trials have recently shown that itraconazole and voriconazole monotherapies are as effective as prednisolone in treating acute-stage ABPA. [Chest. 2018;153(3):656-664|Eur Respir J. 2018;52(3):1801159] In the first randomized trial, 131 ABPA patients were randomized to receive either oral itraconazole (400 mg/day, [n=68]) or prednisolone (n=63) for four months. The proportion of subjects responding at six weeks was significantly higher in the prednisolone arm (100% vs. 88%; p=0.007). However, the number of subjects with exacerbations after one and two years of treatment was similar in the two groups. The time to first exacerbation was also similar in the two groups. The occurrence of adverse reactions was significantly higher in the glucocorticoid arm. Although prednisolone was more effective than itraconazole in inducing a response in acute-stage ABPA, itraconazole with fewer side effects is an acceptable alternative for treating acute-stage ABPA.[Chest. 2018;153(3):656-664] In the second trial, 50 ABPA patients were randomized to receive prednisolone (n=25) or voriconazole (n=25).[Eur Respir J. 2018;52(3):1801159] The response to treatment after six weeks and three months was similar in the two groups. The numbers of subjects with exacerbations after one year and two years were similar in the two groups. More recently, acute-stage ABPA subjects were randomized to receive either prednisolone (n=94) or prednisolone-itraconazole combination (n=97). The one-year exacerbation rate was 33% and 20.6% in the prednisolone and the prednisolone-itraconazole arms, respectively (p=0.054).[Eur Respir J. 2022;59(4):2101787] However, the study did not have a comparator arm of itraconazole monotherapy. Thus, it is unclear whether combination therapy is better than itraconazole or prednisolone monotherapy in reducing the occurrence of ABPA exacerbations. The investigators hypothesize that the combination of prednisolone and itraconazole would significantly reduce the exacerbation rate at one-year than monotherapy. This study will compare the efficacy of prednisolone, itraconazole, or their combination in patients with acute stages of ABPA.


Recruitment information / eligibility

Status Recruiting
Enrollment 300
Est. completion date March 2026
Est. primary completion date November 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Consecutive subjects of acute stage allergic bronchopulmonary aspergillosis (ABPA) complicating asthma per the revised ISHAM-ABPA working group criteria - newly diagnosed subjects with uncontrolled asthma or symptoms or radiology suggesting active lesions attributable to ABPA and meeting the diagnostic criteria of ABPA - those previously meeting the diagnostic criteria for ABPA and presenting with sustained (=2 weeks) clinical or radiological worsening; and increase in serum total IgE by =50% of the last recorded IgE value during clinical stability. Exclusion Criteria: - occurrence of =3 ABPA exacerbations in the last 18 months before enrollment - contraindications to the use of either prednisolone or itraconazole - subjects who have received oral prednisolone (or equivalent) =30 mg for =2 weeks or itraconazole (or voriconazole or posaconazole or isavuconazole) for more than 2 weeks, in the last 3 months - chronic medical illnesses, including uncontrolled diabetes mellitus, chronic renal failure, chronic liver failure, chronic heart failure, and others - patient on immunosuppressive drugs - pregnancy - enrollment in another trial of ABPA - failure to provide informed consent - asthma exacerbation: worsening respiratory symptoms for at least 24 hours without immunological or radiological deterioration of ABPA - infective/bronchiectasis exacerbation: clinical deterioration for at least 24 hours with increase in cough; breathlessness; sputum volume or consistency; sputum purulence; fatigue, malaise, or fever; and hemoptysis without immunological or radiological deterioration of ABPA - serologic ABPA

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Prednisolone
Prednisolone for 4 months
Itraconazole
SUBA-itraconazole for 4 months

Locations

Country Name City State
India Chest Clinic, Dept. of Pulmonary Medicine Chandigarh

Sponsors (1)

Lead Sponsor Collaborator
Post Graduate Institute of Medical Education and Research, Chandigarh

Country where clinical trial is conducted

India, 

Outcome

Type Measure Description Time frame Safety issue
Primary Asthma or ABPA exacerbations Proportion of subjects experiencing exacerbation (asthma or ABPA) 12 months after treatment completion 12 months after treatment completion
Secondary Composite response Proportion of subjects experiencing composite response defined as symptomatic improvement by at least 50%; and, major radiological improvement, and a decline in serum total IgE by at least 20% of baseline 8 weeks
Secondary IgE decline Percentage decline in IgE (baseline IgE minus IgE after eight weeks/baseline IgE 8 weeks
Secondary Time to first ABPA exacerbation Time to first ABPA exacerbation in days 12 months after treatment completion
Secondary Time to first asthma exacerbation Time to first asthma exacerbation in days 12 months after treatment completion
Secondary Weight gain Treatment-related adverse effects Two months
Secondary Hyperglycemia Treatment-related adverse effects Two months
Secondary Cushingoid habitus Treatment-related adverse effects Two months
Secondary Transaminitis Treatment-related adverse effects Two months
See also
  Status Clinical Trial Phase
Completed NCT01222273 - Open-label Vitamin D Trial for Patients With Cystic Fibrosis and Allergic Bronchopulmonary Aspergillosis N/A
Completed NCT04442269 - Investigating Treatment With Dupilumab in Patients With Allergic Bronchopulmonary Aspergillosis (ABPA) (LIBERTY ABPA AIRED) Phase 2
Terminated NCT00787917 - An Exploratory Study to Assess Multiple Doses of Omalizumab in Patients With Cystic Fibrosis Complicated by Acute Bronchopulmonary Aspergillosis (ABPA) Phase 4
Completed NCT02273661 - Evaluation of a Therapeutic Strategy Including Nebulised Liposomal Amphotericin B (Ambisome®) in Maintenance Treatment of Allergic Bronchopulmonary Aspergillosis (Cystic Fibrosis Excluded). Phase 2
Not yet recruiting NCT05129033 - A Prospective Study on Optimizing Treatment for ABPA N/A
Completed NCT02440009 - A Randomized Trial of Itraconazole in Acute Stages of Allergic Bronchopulmonary Aspergillosis Phase 2/Phase 3
Completed NCT01857479 - A Randomized Controlled Trial of Inhaled Amphotericin B for Maintaining Remission in Allergic Bronchopulmonary Aspergillosis Phase 2/Phase 3
Not yet recruiting NCT06244979 - iMagIng pulmonaRy Aspergillosis Using Gallium-68-dEferoxamine Phase 2
Completed NCT00585364 - Mechanisms of Immune Tolerance and Inflammation in Patients With Cystic Fibrosis With ABPA N/A
Completed NCT01621321 - Voriconazole Versus Oral Steroids in Allergic Bronchopulmonary Aspergillosis Phase 2/Phase 3
Recruiting NCT05444946 - Oral Itraconazole Versus Combination of Systemic Glucorticoids and Oral Itraconazole in CPA-ABPA Overlap Syndrome N/A
Terminated NCT03960606 - Study in Adult Asthmatic Patients With Allergic Bronchopulmonary Aspergillosis Phase 2
Active, not recruiting NCT04227483 - Deflazacort vs. Prednisolone in Acute-stage ABPA Phase 2/Phase 3
Withdrawn NCT05903612 - Allergic Bronchopulmonary Aspergillosis Prescreening Study
Completed NCT04229303 - Phase 1 Three Part SAD, MAD & Cross-Over Study of ZP-059 in Healthy and Asthmatic Subjects Phase 1
Completed NCT04476758 - Immune Profiles in CF Fungal Infection
Withdrawn NCT04108962 - Benralizumab in the Treatment of Patients With Severe Asthma With ABPA Phase 4
Completed NCT01321827 - Monotherapy of Itraconazole Versus Prednisolone in Allergic Bronchopulmonary Aspergillosis Phase 2/Phase 3
Completed NCT00974766 - Trial on the Efficacy and Safety of Two Different Glucocorticoid Dose Regimens in Allergic Bronchopulmonary Aspergillosis Phase 2/Phase 3
Completed NCT03059992 - Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment Phase 3